Overview of APCCC
In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options that require careful decision-making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that also are costly and potentially toxic. Further developments in novel next-generation imaging methods, biomarkers, molecular characterization, and genetic assays have led to many open questions and areas for which there is sparse or low-level evidence to support clinical decision-making.
The Advanced Prostate Cancer Consensus Conference (APCCC) was initiated to provide a forum to discuss and debate current questions on the clinical management of men with advanced prostate cancer, with a special focus on these unclear situations. Two days of the conference are dedicated to high-level presentations, discussions, and debates to summarize and conceptualize the available literature and evidence.
The conference concludes with voting by an interdisciplinary expert panel on pre-defined consensus questions targeting areas of clinical relevance. Following the conference, a manuscript with these expert recommendations is published in a peer-reviewed journal (Annals of Oncology in 2015; European Urology in 2017).
Aims of APCCC
- Provide an update on the current standard of advanced prostate cancer management with a focus on situations with no high level evidence for a specific treatment option.
- Advanced prostate cancer is defined by APCCC as locally advanced disease, biochemical recurrence, and metastatic disease.
- Offer a highly educational program consisting of invited lectures, debates, and discussions led by a panel of international and interdisciplinary prostate cancer experts.
- Translate knowledge by summarising and conceptualising current standards of advanced prostate cancer management and disseminating the results of consensus discussions and voting.
- At the end of the meeting, convene these experts to discuss and vote on predefined questions regarding key areas of debate or lack of evidence regarding the optimal treatment of men with advanced prostate cancer. The conference and the development of these questions have been described in detail (see APCCC 2015 and APCCC 2017)
- After the meeting, publish the consensus summary in a high-impact medical journal.
- Conference attendees will be able to participate in the two days of discussions as well as the consensus panel discussion. Attendees are encouraged to interact with panel members to facilitate and encourage international collaboration.
Preview of APCCC 2019 and Interview with Silke Gillessen
The Advanced Prostate Cancer Consensus Conference (APCCC) provides an update on the current standard of advanced prostate cancer management and a global discussion on questions that occur in daily clinical practice for which there is limited evidence-based data. The next APCCC is scheduled for August 29 - 31, 2019 in Basel, Switzerland. To preview the conference, Silke Gillessen, in conversation with Alicia Morgans, discusses many of the changes we have experienced in clinical practice since the last APCCC in 2017. They touch upon new data that is driving these changes and also discuss some unanswered questions that have arisen and will be a focus at the conference, including many new trials, the FDA approval of apalutamide, anticipated approvals of other drugs in M0 CRPC, and data on novel imaging methods. Please click here to see "Preview of the APCCC 2019 - Interview with Silke Gillessen" (Source: www.urotoday.com, 11 April 2018)